Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG013 for Oral Mucositis in Head and Neck Cancer
NCT03234465Phase 2Terminated
- Sponsor
- Oragenics, Inc.
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Gene Editing, Gene Silencing, Live Biotherapeutic Products
- Countries
- 4
01
Overview
A Phase 2 trial of dapatifagene navolactibac in oral mucositis (OM), sponsored by Oragenics, Inc.. Started Jul 2017; status: terminated.
02
Drugs
dapatifagene navolactibac
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT03234465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234465.